images credit
Research Products Contact
The proper initial operation of BReMeL, a biotechnology company with triple direction, dictates the co-financing of primary production of biologics including: recombinant insulin, recombinant Hepatitis-B surface antigen (HBsAg) and an antibiotic. The present investment project has been funded by the National Strategic Reference Framework, NSRF 2007–2013 and the proposed innovation was rated absolutely excellent. We will generate:
a) A new cell line producing profitable insulin levels for commercial exploitation, using a specialized type of human Langerhans beta-cells.
b) Experimental cellular models (disease modeling) - to study the mechanisms of incurable diseases (neurodegenerative diseases, heart disease, etc.) and to test new drugs - by inducing either the differentiation of mesenchymal stem cells (MSCs) or induced pluripotent cells (iPSCs).
In over three years, the NSRF- financed project provides for the massive primary production of three biopharmaceuticals in purified form, in accordance with the requirements of the relevant monographs of the European Pharmacopoeia VIII (Ph.Eur VIII). The procedure that will be applied represents a biotechnological innovation, based on the "cellular lab" of microorganisms and recombinant DNA technology. For more information about BReMel, you can contact with us through the contact form,e-mail or phone
Our goal is your immediate information and convenience.
Welcome to BReMeL

Welcome to the website of BReMeL, a new under-establishment Greek company that aims at generating biotechnological products for use in medical practice and research.

The Greek pharmaceutical industry (GPI) as a whole is metaprattiki, with almost no participation in the primary production of active pharmaceutical ingredients and hence GPI’s survival depends solely on their import from international markets (India, China etc).

The relative decommittment to supply of pure active substances from the foreign sources depends on their autonomic production from domestic companies and this is precisely a key factor in setting-up BReMeL.
The web site is under construction
Copyright © 2014 Bremel